Intracellular and plasma trough concentration and pharmacogenetics of telaprevir

Journal of Pharmacy and Pharmaceutical Sciences

Volumn 18, Issue 2, 2015, Pages 171-176

  Cusato, Jessica ^a   Allegra, Sarah ^a   De Nicolò, Amedeo ^a   Boglione, Lucio ^a   Fatiguso, Giovanna ^a   Abdi, Adnan Mohamed ^a   Cariti, Giuseppe ^a   Di Perri, Giovanni ^a   D ’Avolio, Ant Onio ^a  

^a UNIVERSITY OF TURIN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

COLECALCIFEROL 24 HYDROXYLASE; PEGINTERFERON ALPHA2A PLUS RIBAVIRIN; RIBAVIRIN; TELAPREVIR; ANTIVIRUS AGENT; OLIGOPEPTIDE;

ADULT; ALLELE; ARTICLE; BODY MASS; CHRONIC HEPATITIS C; CLINICAL ARTICLE; COHORT ANALYSIS; CORRELATION ANALYSIS; CYP24A1 GENE; DRUG BLOOD LEVEL; ENANTIOMER; FEMALE; HEPATITIS C VIRUS GENOTYPE 1; HUMAN; HUMAN CELL; MALE; PERIPHERAL BLOOD MONONUCLEAR CELL; PHARMACOGENETICS; REAL TIME POLYMERASE CHAIN REACTION; RETROSPECTIVE STUDY; SINGLE NUCLEOTIDE POLYMORPHISM; STEREOCHEMISTRY; TANDEM MASS SPECTROMETRY; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY; BLOOD; DRUG EFFECTS; GENETICS; HEPACIVIRUS; HEPATITIS C; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MIDDLE AGED; REGRESSION ANALYSIS;

ADULT; ANTIVIRAL AGENTS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; FEMALE; HEPACIVIRUS; HEPATITIS C; HUMANS; MALE; MIDDLE AGED; OLIGOPEPTIDES; PHARMACOGENETICS; POLYMORPHISM, SINGLE NUCLEOTIDE; REAL-TIME POLYMERASE CHAIN REACTION; REGRESSION ANALYSIS; RETROSPECTIVE STUDIES; RIBAVIRIN; TANDEM MASS SPECTROMETRY;

EID: 84931259829     PISSN: None     EISSN: 14821826     Source Type: Journal    
DOI: 10.18433/j3dk6t     Document Type: Article

References (30)

1. Perry CM. Telaprevir: a review of its use in the management of genotype 1 chronic hepatitis C. Drugs. 2012 Mar 26;72(5):619-41.
2. FDA. Center for Drug Evaluation and Research: 202258Orig1s000 – BOCEPREVIR, 2011. 2011; 2011:[Available from: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/202258Orig1s000MedR.pdf.
3. Kim DY, Ahn SH, Han KH. Emerging Therapies for Hepatitis C. Gut Liver. 2014 Sep;8(5):471-9.
4. D'Avolio A, De Nicolo A, Agnesod D, Simiele M, Mohamed Abdi A, Dilly Penchala S, et al. A UPLC-MS/MS method for the simultaneous plasma quantification of all isomeric forms of the new anti-HCV protease inhibitors boceprevir and telaprevir. J Pharm Biomed Anal. 2013 May 5;78-79:217-23.
5. Jacobson IM, McHutchison JG, Dusheiko G, Di Bisceglie AM, Reddy KR, Bzowej NH, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med. 2011 Jun 23;364(25):2405-16.
6. De Nicolo A, Boglione L, Ciancio A, Cusato J, Strona S, Cardellino CS, et al. Telaprevir-S isomer enhances ribavirin exposure and the ribavirinrelated haemolytic anaemia in a concentrationdependent manner. Antiviral Res. 2014 Jun 20.
7. Boglione L, De Nicolo A, Cusato J, Cariti G, Di Perri G, D'Avolio A. Significant early higher ribavirin plasma concentrations in patients receiving a triple therapy with pegylated interferon, ribavirin and telaprevir. J Viral Hepat. 2014 Apr;21(4):260-3.
8. Mauss S, Hueppe D, Alshuth U. Renal impairment is frequent in chronic hepatitis C patients under triple therapy with telaprevir or boceprevir. Hepatology. 2013 Jan;59(1):46-8.
9. Hammond K, Jimmerson L, MacBrayne C, Ray M, Bushman L, Burton J, et al. PP_02 Increased Plasma and Intracellular Ribavirin Concentrations Associated with Telaprevir Use. Reviews in antiviral therapy & infectious diseases. 2013;3:26.
10. D'Avolio A, Carcieri C, Cusato J, Simiele M, Calcagno A, Allegra S, et al. Intracellular accumulation of atazanavir/ritonavir according to plasma concentrations and OATP1B1, ABCB1 and PXR genetic polymorphisms. J Antimicrob Chemother. 2014 Jul 4.
11. D'Avolio A, Pensi D, Baietto L, Di Perri G. Therapeutic drug monitoring of intracellular antiinfective agents. J Pharm Biomed Anal. 2014 Apr 3.
12. De Francia S, D'Avolio A, Ariaudo A, Pirro E, Piccione F, Simiele M, et al. Plasma and intracellular imatinib concentrations in patients with chronic myeloid leukemia. Ther Drug Monit. 2013 Jun;36(3):410-2.
13. De Nicolo A, Simiele M, Calcagno A, Abdi AM, Bonora S, Di Perri G, et al. Intracellular antiviral activity of low-dose ritonavir in boosted protease inhibitor regimens. Antimicrob Agents Chemother. 2014 Jul;58(7):4042-7.
14. Jessica Cusato, Sarah Allegra, Amedeo De Nicolò, Lucio Boglione, Giovanna Fatiguso, Giuseppe Cariti, et al. ABCB11 and ABCB1 gene polymorphisms impact on telaprevir pharmacokinetic at one month of therapy. Biomedicine & Pharmacotherapy 2014;accepted.
15. Allegra S, Cusato J, Nicolò AD, Boglione L, Gatto A, Cariti G, et al. Role of pharmacogenetic in ribavirin outcome prediction and pharmacokinetics in an Italian cohort of HCV-1 and 4 patients Biomedicine & Pharmacotherapy 2014 6/11/2014;11.
16. D'Avolio A, Ibanez A, Sciandra M, Siccardi M, de Requena DG, Bonora S, et al. Validation of liquid/liquid extraction method coupled with HPLC-UV for measurement of ribavirin plasma levels in HCV-positive patients. J Chromatogr B Analyt Technol Biomed Life Sci. 2006 May 1;835(1-2):127-30.
17. De Nicolò A, Abdi AM, Boglione L, Baietto L, Pensi D, Allegra S, et al. UPLC-MS/MS coupled with automated on-line SPE method for the isomerspecific quantification of the first-generation anti-HCV protease inhibitors in peripheral blood mononuclear cells. Journal of Chromatography AJournal of Chromatography A. 2014;submitted.
18. Perni RB, Almquist SJ, Byrn RA, Chandorkar G, Chaturvedi PR, Courtney LF, et al. Preclinical profile of VX-950, a potent, selective, and orally bioavailable inhibitor of hepatitis C virus NS3-4A serine protease. Antimicrob Agents Chemother. 2006 Mar;50(3):899-909.
19. Vertex. INCIVEK (telaprevir). United States prescribing information 2012. Cambridge, MA, USA2012 [updated June 201211 July 2012]; Available from: http://pi.vrtx.com/files/uspi_telaprevir.pdf.
20. Weiss J, Becker JP, Haefeli WE. Telaprevir is a substrate and moderate inhibitor of P-glycoprotein, a strong inductor of ABCG2, but not an activator of PXR in vitro. Int J Antimicrob Agents. 2014 Feb;43(2):184-8.
21. Marcellin P, Forns X, Goeser T, Ferenci P, Nevens F, Carosi G, et al. Telaprevir is effective given every 8 or 12 hours with ribavirin and peginterferon alfa-2a or-2b to patients with chronic hepatitis C. Gastroenterology. 2011 Feb;140(2):459-68 e1; quiz e14.
22. De Nicolo A, Boglione L, Ciancio A, Cusato J, Strona S, Cardellino CS, et al. Telaprevir-S isomer enhances ribavirin exposure and the ribavirinrelated haemolytic anaemia in a concentrationdependent manner. Antiviral Res. 2014 Sep;109:7-14.
23. Tempestilli M, Lionetti R, D'Offizi G, Montalbano M, Giaffreda A, Fazio S, et al. Increased plasma concentration of ribavirin as a result of renal dysfunction in hepatitis C virus patients treated with telaprevir. Hepatology. 2014 Sep;60(3):1109-10.
24. Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature. 2009 Sep 17;461(7262):399-401.
25. Thimme R, Bukh J, Spangenberg HC, Wieland S, Pemberton J, Steiger C, et al. Viral and immunological determinants of hepatitis C virus clearance, persistence, and disease. Proc Natl Acad Sci U S A. 2002 Nov 26;99(24):15661-8.
26. Poon AH, Gong L, Brasch-Andersen C, Litonjua AA, Raby BA, Hamid Q, et al. Very important pharmacogene summary for VDR. Pharmacogenet Genomics. 2012 Oct;22(10):758-63.
27. Holt SK, Kwon EM, Koopmeiners JS, Lin DW, Feng Z, Ostrander EA, et al. Vitamin D pathway gene variants and prostate cancer prognosis. Prostate. 2010 Sep 15;70(13):1448-60.
28. Cusato J, Allegra S, Boglione L, De Nicolo A, Baietto L, Cariti G, et al. Vitamin D pathway gene variants and HCV-2/3 therapy outcomes. Antivir Ther. 2014 Oct 3.
29. Furusyo N, Ogawa E, Murata M, Toyoda K, Ohnishi H, Eiraku K, et al. Therapeutic drug monitoring of telaprevir in chronic hepatitis C patients receiving telaprevir-based triple therapy is useful for predicting virological response. J Antimicrob Chemother. 2014 Feb;69(2):483-90.
30. Cusato J, Allegra S, Nicolò AD, Boglione L, Fatiguso G, Abdi AM, et al. Intracellular accumulation of boceprevir according to plasma concentrations and pharmacogenetics. International Journal of Antimicrobial Agents. 2015